QuidelOrtho's revenue has contracted for consecutive periods, falling 11.6% year over year to $618.9M in 2026Q3, while operating margin remained negative at -1.2% and quarterly EPS stood at -$0.78, suggesting the post-pandemic demand reset has not yet produced a stable growth base.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.31+53.6% vs $0.20 | $619M-1.4% vs $628M |
Q3 2026 Aug 6, 2026 | $0.13+366.2% vs -$0.05 | $631M+2.0% vs $619M |
Q2 2026 May 5, 2026 | -$0.04-110.8% vs $0.37 | $620M-6.8% vs $665M |
Q1 2026 Feb 11, 2026 | $0.46+7.0% vs $0.43 | $724M+3.3% vs $701M |
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother. Laboratories are facing increasing complexity and growing testing demand.
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 ended September 27, 2026, shortly after the market closes at 4:00 p.m. ET on Tuesday, November 3, 2026.
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Elutia (NASDAQ: ELUT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Profitability This table compares QuidelOrtho and Elutia's net margins,
SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to each employee's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Benchmark QDEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for QuidelOrtho Corporation (QDEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.70 | $729.64M | -1.99 | -1.89% | -14.24% | -20.13% | — | |
| $381.57 | $10.27B | 10.05 | 0.65% | 39.45% | 14.07% | — | |
| $11.76 | $2.56B | -45.71 | -2.71% | -6.35% | -2.68% | — | |
| $676.04 | $53.33B | 45.20 | 10.42% | 25.36% | 71.18% | — | |
| $166.00 | $11.89B | 23.97 | 0.9% | 11.83% | 11.76% | — | |
| $3.44 | $236.84M | -4.91 | -38.1% | -43.7% | -14.73% | — |
QuidelOrtho Corporation (QDEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
QuidelOrtho Corporation (QDEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 6, 2026·SEC
Jun 23, 2026·SEC
Get notified when QDEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QuidelOrtho Corporation (QDEL) stock FAQ — growth, dividends, profitability & financials explained
QuidelOrtho Corporation (QDEL) reported $2.59B in revenue over the trailing twelve months. Revenue was $2.73B in fiscal year 2025. That is 7814% more than the $34.5M of fiscal year 1995.
QuidelOrtho Corporation (QDEL) revenue fell by 4.5% over the trailing twelve months, compared with the twelve months before.
No. QuidelOrtho Corporation (QDEL) reported a net loss of $369.2M over the trailing twelve months.
QuidelOrtho Corporation (QDEL) had a return on equity (ROE) of -20.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
QuidelOrtho Corporation (QDEL) had negative free cash flow of $117.9M over the trailing twelve months.
